Ritonavir and Agenerase Treatment for Patients Who Have Failed Previous Anti-HIV Treatment
This trial is active, not recruiting.
|Sponsor||Gathe, Joseph, M.D.|
|Trial identifier||NCT00006591, 313A, APV-430|
The purpose of this study is to determine if treatment with an anti-HIV drug containing ritonavir and Agenerase is safe and can lower the level of HIV in the blood in patients who have failed an anti-HIV drug treatment containing nelfinavir.
|Endpoint classification||safety study|
Male or female participants at least 18 years old.
Inclusion Criteria Patients may be eligible for this study if they: - Are 18 years of age or older. - Are HIV-positive. - Have a viral load (level of HIV in the body) of more than 1,000 copies/ml. - Have had more than 12 weeks of prior anti-HIV drug treatment. - Have failed a previous anti-HIV treatment containing nelfinavir as the only protease inhibitor. - Are responsive to Agenerase. - Are able to follow study requirements. Exclusion Criteria Patients will not be eligible for this study if they: - Are intolerant to ritonavir (an anti-HIV drug). - Have or have had problems with absorption. - Have liver disease or damage. - Have pancreatic disease or damage. - Have taken any protease inhibitor other than nelfinavir. - Are receiving investigational drugs or devices from another study. - Are pregnant or breast-feeding. - Currently use triazolam, astemizole, ergot medications, cisapride, midazolam, bepridil, rifampin, terfenadine, or pimozide. - Have a bleeding disorder. - Have previously been treated with Agenerase. - Are receiving nonnucleosides.
|Official title||The Safety and Efficacy of a Ritonavir-Enhanced Agenerase Regimen as Salvage Therapy in HIV-Infected Individuals|
|Description||HIV-infected patients will be treated with a ritonavir-enhanced Agenerase regimen.|
Call for more information